![Keith Orford](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Keith Orford
Director/Board Member at CALITHERA BIOSCIENCES, INC.
Net worth: 1 $ as of 2024-06-29
Profile
Keith Orford is a Non-Independent Director at Calithera Biosciences, Inc. since 2015.
He is also currently serving as the Chief Medical Officer & Executive VP-Clinical at Fog Pharmaceuticals, Inc. since 2021.
Prior to his current positions, Keith worked at GSK Plc from 2010 to 2015 as a Clinical Development Lead-Immuno-Oncology.
He holds a doctorate degree from Georgetown University.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2023-04-29 | 54 ( 0.00% ) | 1 $ | 2024-06-29 |
Keith Orford active positions
Companies | Position | Start |
---|---|---|
CALITHERA BIOSCIENCES, INC. | Director/Board Member | 2021-11-04 |
Fog Pharmaceuticals, Inc.
![]() Fog Pharmaceuticals, Inc. BiotechnologyHealth Technology Fog Pharmaceuticals, Inc. develops pharmaceutical products. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 2021-10-31 |
Former positions of Keith Orford
Companies | Position | End |
---|---|---|
GSK PLC | Corporate Officer/Principal | 2014-12-31 |
Training of Keith Orford
Georgetown University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
CALITHERA BIOSCIENCES, INC. | Health Technology |
GSK PLC | Health Technology |
Private companies | 1 |
---|---|
Fog Pharmaceuticals, Inc.
![]() Fog Pharmaceuticals, Inc. BiotechnologyHealth Technology Fog Pharmaceuticals, Inc. develops pharmaceutical products. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Keith Orford